Geneva will not market generic captopril until February under consent agreement reached Nov. 20.
GENEVA GENERIC CAPTOPRIL WILL NOT BE DISTRIBUTED UNTIL FEBRUARY under a consent agreement reached Nov. 20, CibaGeneva said. The company will hold off marketing a generic version of Bristol-Myers Squibb's ACE inhibitor Capoten until Bristol's GATT-extended patent expires Feb. 13, unless Congress amends the Waxman/Hatch Act to allow companies to market generics in the delta period between the original and the General Agreement on Tariffs & Trade expiration dates.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth